Evidence map›Paper›PMID 23405125›Full record

ArticlePloS one2013

Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D.

Daniel E Adkins, Renan P Souza, Karolina Aberg, Shaunna L Clark, Joseph L McClay, Patrick F Sullivan, Edwin J C G van den Oord

Abstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Pooled it
  2. Pooled it
  3. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel E AdkinsCenter for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA.
Renan P Souza
Karolina Aberg
Shaunna L Clark
Joseph L McClay
Patrick F Sullivan
Edwin J C G van den Oord

Funding

2/2 A genome-wide association study to detect genetic variation for schizophreniaR01MH080403 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SULLIVAN, PATRICK F · 2008 to 2010
$4.5M
A genome-wide association study to detect genetic variation for schizophreniaR01MH078069 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI VAN DEN OORD, EDWIN · 2008 to 2010
$905k
Integrating Genomic and Environmental Perspectives on Internalizing DisordersK01MH093731 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI ADKINS, DANIEL E · 2011 to 2015
$649k
Investigating Methylation Patterns Associated with Alcohol Use and AddictionK01AA021266 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI CLARK, SHAUNNA L · 2012 to 2016
$580k
NIAAA NIH HHS K01 AA021266NIMH NIH HHS K01 MH093731NIMH NIH HHS K01MH093731NIMH NIH HHS R01 MH078069NIMH NIH HHS R01MH078069NIMH NIH HHS R01 MH080403NIMH NIH HHS R01MH080403
6 · The paper itself

Abstract

Only a subset of patients will typically respond to any given prescribed drug. The time it takes clinicians to declare a treatment ineffective leaves the patient in an impaired state and at unnecessary risk for adverse drug effects. Thus, diagnostic tests robustly predicting the most effective and safe medication for each patient prior to starting pharmacotherapy would have tremendous clinical value. In this article, we evaluated the use of genetic markers to estimate ancestry as a predictive component of such diagnostic tests. We first estimated each patient's unique mosaic of ancestral backgrounds using genome-wide SNP data collected in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) (n = 765) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (n = 1892). Next, we performed multiple regression analyses to estimate the predictive power of these ancestral dimensions. For 136/89 treatment-outcome combinations tested in CATIE/STAR*D, results indicated 1.67/1.84 times higher median test statistics than expected under the null hypothesis assuming no predictive power (p<0.01, both samples). Thus, ancestry showed robust and pervasive correlations with drug efficacy and side effects in both CATIE and STAR*D. Comparison of the marginal predictive power of MDS ancestral dimensions and self-reported race indicated significant improvements to model fit with the inclusion of MDS dimensions, but mixed evidence for self-reported race. Knowledge of each patient's unique mosaic of ancestral backgrounds provides a potent immediate starting point for developing algorithms identifying the most effective and safe medication for a wide variety of drug-treatment response combinations. As relatively few new psychiatric drugs are currently under development, such personalized medicine offers a promising approach toward optimizing pharmacotherapy for psychiatric conditions.

Indexed as

Genome-Wide Association StudyPolymorphism, Single NucleotideGenetic MarkersGenetic TestingGenome, HumanGenotypeHumansPrecision MedicinePrescription DrugsSelf ReportTreatment OutcomeGenetic MarkersPrescription Drugs

Identifiers

PMID23405125
PMCPMC3566192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.